Malignant Potential of Oral Lichen Planus/Lichenoid Lesions Malignant Potential of Oral Lichen Planus/Lichenoid Lesions
This new meta-analysis supports the concept that OLP and OLLs are associated with a small, yet measurable, increased risk for malignant transformation.Medscape Dental &Oral Health
Publication date: Available online 25 March 2020Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyAuthor(s): Alessandro Villa, Vidya Sankar, Gus Bassani, Lisa Bennett Johnson, Herve Sroussi
Publication date: Available online 20 March 2020Source: Biochimica et Biophysica Acta (BBA) - General SubjectsAuthor(s): Fang Wang, Jing Zhang, Gang Zhou
Conclusions: The optimised TOPICOP scale proved valuable as a PROM in OLP. TCs phobia can be a real consideration in OLP, nonetheless, it does not appear to be an impediment to treatment adherence. PMID: 32189543 [PubMed - as supplied by publisher]
Evaluation of synuclein-γ levels by novel monoclonal antibody in saliva and cancer tissues from oral squamous cell carcinoma patients. Neoplasma. 2020 Mar 18;: Authors: Wang K, Shen Y, Xu J, Li Z, Liu Y, Yu C, Peng L, Zheng J, Zeng Y Abstract The clinical value of synuclein-γ (SNCG) in oral squamous cell carcinoma (OSCC) was evaluated by detecting the expression of SNCG in saliva and tissues and its correlation with clinicopathological parameters (age, gender, ethnicity, degree of differentiation, clinical stage and lymph node metastasis). Salivary samples were collected from 79 patients w...
PMID: 32176308 [PubMed - as supplied by publisher]
The aim of this study was to investigate the prevalence and genotypic profiles of Candida albicans in patients with oral lichen planus (OLP).
Condition: Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris Interventions: Drug: Cutaneous lichen planus secukinumab 300 mg Q4W; Drug: Cutaneous lichen planus placebo; Drug: Mucosal lichen planus placebo; Drug: Lichen planopilaris placebo; Drug: Mucosal lichen planus secukinumab 300 mg Q4W; Drug: Lichen planopilaris secukinumab 300 mg Q4 W Sponsor: Novartis Pharmaceuticals Not yet recruiting
CONCLUSION: The combination of TCA and topical steroids offers a good alternative for the treatment of hypertrophic lichen planus. PMID: 32164922 [PubMed - as supplied by publisher]
CONCLUSIONS: This review study shows that IL-4 plays a key role in the development of OLP. According to the past studies, there are several factors contributing to the production of this cytokine. Identification of the routes of production of IL-4 and its role in OLP might be useful for development of new preventive and therapeutic methods in management of patients with OLP. PMID: 32134902 [PubMed - as supplied by publisher]
PMID: 32141608 [PubMed - as supplied by publisher]